ReferenceCitation: Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 Oct 15;124(20):4032-4043. doi: 10.1002/cncr.31680. Epub 2018 Sep 11.

name: National and Kapodistrian University of Athens School of Medicine Athens Greece

family: Dimopoulos

full_name: Meletios A. Dimopoulos

given: Meletios A.

name: Winship Cancer Institute, Emory University School of Medicine Atlanta Georgia

family: Lonial

full_name: Sagar Lonial

given: Sagar

name: Analysis Group Inc, Boston Massachusetts

family: Betts

full_name: Keith A. Betts

given: Keith A.

name: Bristol‐Myers Squibb Princeton New Jersey

family: Chen

full_name: Clara Chen

given: Clara

family: Zichlin

full_name: Miriam L. Zichlin

given: Miriam L.

family: Brun

full_name: Alexander Brun

given: Alexander

family: Signorovitch

full_name: James E. Signorovitch

given: James E.

family: Makenbaeva

full_name: Dinara Makenbaeva

given: Dinara

family: Mekan

full_name: Sabeen Mekan

given: Sabeen

family: Sy

full_name: Oumar Sy

given: Oumar

family: Weisel

full_name: Katja Weisel

given: Katja

name: Dana‐Farber Cancer Institute Boston Massachusetts

family: Richardson

full_name: Paul G. Richardson

given: Paul G.

journal_name: Cancer

title: Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

ReferenceCitation: Passey C, Mora J, Dodge R, Gibiansky L, Sheng J, Roy A, Bello A, Gupta M. An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab. AAPS J. 2017 Mar;19(2):557-567. doi: 10.1208/s12248-016-0033-9. Epub 2017 Jan 9.

family: Passey

full_name: Chaitali Passey

given: Chaitali

family: Mora

full_name: Johanna Mora

given: Johanna

family: Dodge

full_name: Robert Dodge

given: Robert

family: Gibiansky

full_name: Leonid Gibiansky

given: Leonid

family: Sheng

full_name: Jennifer Sheng

given: Jennifer

family: Roy

full_name: Amit Roy

given: Amit

family: Bello

full_name: Akintunde Bello

given: Akintunde

family: Gupta

full_name: Manish Gupta

given: Manish

ReferenceCitation: Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.

repository_institution: University of Turin - Institutional Research Information System University of Turin

location_country:
Greece
Romania
Australia
Belgium
Denmark
France
Japan
Poland
Canada
United Arab Emirates
Switzerland
Hungary
Ireland
Puerto Rico
United States
Germany
United Kingdom
Italy
Austria
Czechia
Israel
Spain
Turkey

location_facility: University Of Oklahoma Health Sciences Center

location_facility: University Of Texas Md Anderson Cancer Ctr

location_facility: University Of Wisconsin Hospital And Clinics

location_facility: Capitol Comprehensive Cancer Care Center

location_facility: San Diego Pacific Oncology& Hematology Associates, Inc

location_facility: Acrc/Arizona Clinical Research Center, Inc.

location_facility: Cancer Center Of Acadiana At Lafayette General

location_facility: Hematology-Oncology Associates Of Fredricksburg, Inc

location_facility: Washington University School Of Medicine

title: Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)

summary: The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).


title: ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset

summary: To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to placebo-treated patients will result in an improved clinical outcome without increase of fatality rate.

status: Completed

study_type: Interventional

primary_purpose: Treatment

enrollment_type: Actual

ReferenceType: derived

ReferenceCitation: Alper BS, Foster G, Thabane L, Rae-Grant A, Malone-Moses M, Manheimer E. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances. BMJ Evid Based Med. 2020 Oct;25(5):168-171. doi: 10.1136/bmjebm-2020-111386. Epub 2020 May 19.

family: Alper

full_name: Brian Scott Alper

given: Brian Scott

sequence: first

family: Foster

full_name: Gary Foster

given: Gary

sequence: additional

family: Thabane

full_name: Lehana Thabane

given: Lehana

family: Rae-Grant

full_name: Alex Rae-Grant

given: Alex

family: Malone-Moses

full_name: Meghan Malone-Moses

given: Meghan

family: Manheimer

full_name: Eric Manheimer

given: Eric

bso_classification: Medical research

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: BMJ Evidence-Based Medicine

oa_colors: green hybrid

oa_host_type: publisher;repository

evidence: open (via page says license)

host_type: publisher

license: cc-by-nc

license_normalized: cc-by-nc

version: publishedVersion

evidence: oa repository (via pmcid lookup)

host_type: repository

license_normalized: no license

repository_normalized: PubMed Central

publisher: BMJ

publisher_dissemination: British Medical Journal

publisher_group: British Medical Journal

publisher_normalized: British Medical Journal

title: Thrombolysis with alteplase 3–4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances

ReferenceCitation: Bluhmki E, Chamorro A, Dávalos A, Machnig T, Sauce C, Wahlgren N, Wardlaw J, Hacke W. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009 Dec;8(12):1095-102. doi: 10.1016/S1474-4422(09)70264-9. Epub 2009 Oct 21.

family: Bluhmki

full_name: Erich Bluhmki

given: Erich

family: Chamorro

full_name: Ángel Chamorro

given: Ángel

family: Dávalos

full_name: Antoni Dávalos

given: Antoni

family: Machnig

full_name: Thomas Machnig

given: Thomas

family: Sauce

full_name: Christophe Sauce

given: Christophe

family: Wahlgren

full_name: Nils Wahlgren

given: Nils

family: Wardlaw

full_name: Joanna Wardlaw

given: Joanna

family: Hacke

full_name: Werner Hacke

given: Werner

journal_name: The Lancet Neurology

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

title: Stroke treatment with alteplase given 3·0–4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial

ReferenceCitation: Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.

family: Kaste

full_name: Markku Kaste

given: Markku

title: Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

location_country:
Italy
Austria
Sweden
Switzerland
Netherlands
Spain
United Kingdom
Finland
France
Poland
Greece
Slovakia
Norway
Hungary
Belgium
Portugal
Denmark
Germany
Czech Republic

location_facility: 135.312.44023 Boehringer Ingelheim Investigational Site

location_facility: 135.312.48001 Institute of Psychiatry & Neurology in Warsaw

location_facility: 135.312.33011 Boehringer Ingelheim Investigational Site

location_facility: 135.312.43001 Boehringer Ingelheim Investigational Site

location_facility: 135.312.43013 Boehringer Ingelheim Investigational Site

location_facility: 135.312.46005 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33012 Boehringer Ingelheim Investigational Site

location_facility: 135.312.49002 Boehringer Ingelheim Investigational Site

location_facility: 135.312.48006 Wojewodship Specialistic Neuropsychiatric Centre in Opole

location_facility: 135.312.49014 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33019 Boehringer Ingelheim Investigational Site

location_facility: 135.312.30004 Boehringer Ingelheim Investigational Site

location_facility: 135.312.44003 Boehringer Ingelheim Investigational Site

location_facility: 135.312.43003 Boehringer Ingelheim Investigational Site

location_facility: 135.312.34009 Boehringer Ingelheim Investigational Site

location_facility: 135.312.48002 Dr. Anna Gostynska Wolski Hospital

location_facility: 135.312.49009 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33022 Boehringer Ingelheim Investigational Site

location_facility: 135.312.39025 Università di Roma "La Sapienza"

location_facility: 135.312.34003 Boehringer Ingelheim Investigational Site

location_facility: 135.312.49020 Boehringer Ingelheim Investigational Site

location_facility: 135.312.46003 Boehringer Ingelheim Investigational Site

location_facility: 135.312.49011 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33006 Boehringer Ingelheim Investigational Site

location_facility: 135.312.43004 Boehringer Ingelheim Investigational Site

location_facility: 135.312.35105 Hospital de São Sebastião, EPE

location_facility: 135.312.49037 Boehringer Ingelheim Investigational Site

location_facility: 135.312.46007 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33003 Boehringer Ingelheim Investigational Site

location_facility: 135.312.39002 A. O. di Padova - Policlinico Universitario

location_facility: 135.312.41002 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33023 Boehringer Ingelheim Investigational Site

location_facility: 135.312.39009 Ospedale Maggiore di BorgoTrento

location_facility: 135.312.41001 Boehringer Ingelheim Investigational Site

location_facility: 135.312.39016 A. O. Ospedale Santa Corona

location_facility: 135.312.43008 Boehringer Ingelheim Investigational Site

location_facility: 135.312.45004 Boehringer Ingelheim Investigational Site

location_facility: 135.312.39003 A. O. Arcispedale "Santa Maria Nuova"

location_facility: 135.312.44026 Boehringer Ingelheim Investigational Site

location_facility: 135.312.44030 Boehringer Ingelheim Investigational Site

location_facility: 135.312.34017 Boehringer Ingelheim Investigational Site

location_facility: 135.312.32016 Boehringer Ingelheim Investigational Site

location_facility: 135.312.47006 Boehringer Ingelheim Investigational Site

location_facility: 135.312.47003 Boehringer Ingelheim Investigational Site

location_facility: 135.312.43010 Boehringer Ingelheim Investigational Site

location_facility: 135.312.49003 Boehringer Ingelheim Investigational Site

location_facility: 135.312.42002 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33016 Boehringer Ingelheim Investigational Site

location_facility: 135.312.35805 Boehringer Ingelheim Investigational Site

location_facility: 135.312.34014 Boehringer Ingelheim Investigational Site

location_facility: 135.312.36006 BAZ County and Teaching Hospital

location_facility: 135.312.33001 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33021 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33005 Boehringer Ingelheim Investigational Site

location_facility: 135.312.48005 Dept. of Neurology, Regenerative and Cerebrovascular Disease

location_facility: 135.312.39001 A. O. Policlinico Umberto I

location_facility: 135.312.35101 Hospitais da Universidade de Coimbra

location_facility: 135.312.45005 Boehringer Ingelheim Investigational Site

location_facility: 135.312.39005 A. O. di Perugia - Policlinico Monteluce

location_facility: 135.312.33002 Boehringer Ingelheim Investigational Site

location_facility: 135.312.39024 Istituto Scientifico San Raffaele

location_facility: 135.312.36001 Aladár Petz County Hospital

location_facility: 135.312.39018 Ospedale S. Maria della Misericordia

location_facility: 135.312.49008 Boehringer Ingelheim Investigational Site

location_facility: 135.312.43006 Boehringer Ingelheim Investigational Site

location_facility: 135.312.46002 Boehringer Ingelheim Investigational Site

location_facility: 135.312.42004 Boehringer Ingelheim Investigational Site

location_facility: 135.312.49018 Boehringer Ingelheim Investigational Site

location_facility: 135.312.30002 Boehringer Ingelheim Investigational Site

location_facility: 135.312.34019 Boehringer Ingelheim Investigational Site

location_facility: 135.312.45001 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33007 Boehringer Ingelheim Investigational Site

location_facility: 135.312.34001 Boehringer Ingelheim Investigational Site

location_facility: 135.312.34018 Boehringer Ingelheim Investigational Site

location_facility: 135.312.39019 Ospedale Santa Maria Annunziata

location_facility: 135.312.44025 Boehringer Ingelheim Investigational Site

location_facility: 135.312.48004 Medical University of Gdansk

location_facility: 135.312.49038 Boehringer Ingelheim Investigational Site

location_facility: 135.312.49005 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33008 Boehringer Ingelheim Investigational Site

location_facility: 135.312.32002 Boehringer Ingelheim Investigational Site

location_facility: 135.312.44002 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33017 Boehringer Ingelheim Investigational Site

location_facility: 135.312.34007 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33018 Boehringer Ingelheim Investigational Site

location_facility: 135.312.34011 Boehringer Ingelheim Investigational Site

location_facility: 135.312.30005 Boehringer Ingelheim Investigational Site

location_facility: 135.312.43002 Boehringer Ingelheim Investigational Site

location_facility: 135.312.43007 Boehringer Ingelheim Investigational Site

location_facility: 135.312.32005 Boehringer Ingelheim Investigational Site

location_facility: 135.312.35802 Boehringer Ingelheim Investigational Site

location_facility: 135.312.49031 Boehringer Ingelheim Investigational Site

location_facility: 135.312.49025 Boehringer Ingelheim Investigational Site

location_facility: 135.312.42105 Boehringer Ingelheim Investigational Site

location_facility: 135.312.44024 Boehringer Ingelheim Investigational Site

location_facility: 135.312.32001 Boehringer Ingelheim Investigational Site

location_facility: 135.312.32011 Boehringer Ingelheim Investigational Site

location_facility: 135.312.49041 Boehringer Ingelheim Investigational Site

location_facility: 135.312.49001 Boehringer Ingelheim Investigational Site

location_facility: 135.312.49006 Boehringer Ingelheim Investigational Site

location_facility: 135.312.34002 Boehringer Ingelheim Investigational Site

location_facility: 135.312.35801 Boehringer Ingelheim Investigational Site

location_facility: 135.312.44006 Boehringer Ingelheim Investigational Site

location_facility: 135.312.39013 A. O. Universitaria di Careggi

location_facility: 135.312.49023 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33010 Boehringer Ingelheim Investigational Site

location_facility: 135.312.49017 Boehringer Ingelheim Investigational Site

location_facility: 135.312.41003 Boehringer Ingelheim Investigational Site

location_facility: 135.312.34006 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33013 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33004 Boehringer Ingelheim Investigational Site

location_facility: 135.312.42001 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33015 Boehringer Ingelheim Investigational Site

location_facility: 135.312.45002 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33020 Boehringer Ingelheim Investigational Site

location_facility: 135.312.32014 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33014 Boehringer Ingelheim Investigational Site

location_facility: 135.312.49004 Boehringer Ingelheim Investigational Site

location_facility: 135.312.43012 Boehringer Ingelheim Investigational Site

location_facility: 135.312.46004 Boehringer Ingelheim Investigational Site

location_facility: 135.312.34010 Boehringer Ingelheim Investigational Site

location_facility: 135.312.42104 Jessenius Faculty of Medicine Commenius University

location_facility: 135.312.33024 Boehringer Ingelheim Investigational Site

location_facility: 135.312.33009 Boehringer Ingelheim Investigational Site

location_facility: 135.312.41004 Boehringer Ingelheim Investigational Site

location_facility: 135.312.44018 Boehringer Ingelheim Investigational Site

location_facility: 135.312.34020 Boehringer Ingelheim Investigational Site

location_facility: 135.312.47001 Boehringer Ingelheim Investigational Site


title: A Long Term Open Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV-1 Infected Subjects

summary: The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg ritonavir BID) when administered with other antiretroviral medications.

design_allocation: Non-Randomized

lead_sponsor: Boehringer Ingelheim

location_country:
Italy
Austria
Brazil
Switzerland
Mexico
Netherlands
Germany
Spain
France
Greece
Argentina
Australia
Belgium
Portugal
Denmark
United States
United Kingdom
Canada

location_facility: 1182.17.33022 Hôpital Européen Georges Pompidou

location_facility: 1182.17.6 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.906 Infectious Diseases & HIV - St. Michael's Hospital

location_facility: 1182.17.116 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.3502 Hospital Condes Castro Guimarães

location_facility: 1182.17.95 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.5405 Dpto. de Enfermedades infecciosas (Pabellón 22)

location_facility: 1182.17.111 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.15 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.3209 Instituut Tropische Geneeskunde

location_facility: 1182.17.3010 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.5506 Centro de Referência e Treinamento - DST/AIDS

location_facility: 1182.17.62 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.0385 IRCCS Policlinico San Matteo

location_facility: 1182.17.3202 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.0394 IRCCS Policlinico San Matteo

location_facility: 1182.17.22 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4502 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.914 Montreal General Hospital - McGill University Health Centre

location_facility: 1182.17.37 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.3002 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.92 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4103 DIM / Abteilung für Infektiologie

location_facility: 1182.17.3 Division of Infectious Diseases

location_facility: 1182.17.3108 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.97 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.0384 Azienda Ospedaliera Arcispedale S. Anna

location_facility: 1182.17.3207 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.5203 Hospital Civil Nuevo de Guadalajara

location_facility: 1182.17.77 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.1 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.76 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.11 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.5406 Pabellón de Clínicas 2° Piso

location_facility: 1182.17.59 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.32 University of Kansas School of Medicine - Wichita

location_facility: 1182.17.4924 Klinikum der J. W.-Goethe-Universität

location_facility: 1182.17.0415 U.O.A. Malattie Infettive B

location_facility: 1182.17.4920 Abteilung Klinische Immunologie

location_facility: 1182.17.5503 Instituto de Infectologia Emílio Ribas

location_facility: 1182.17.5509 (Unidade de Testes Terapêuticos)

location_facility: 1182.17.3001 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4916 Medizinisches Versorgungszentrum Hamburg

location_facility: 1182.17.103 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.0411 Presidio Ospedaliero "A. Manzoni"

location_facility: 1182.17.112 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.5511 Universidade Federal da Bahia

location_facility: 1182.17.4504 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.114 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.50 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.202 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.24 Hackensack University Medical Center

location_facility: 1182.17.132 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.10 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.407 Holdsworth House General Practice

location_facility: 1182.17.64 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.43 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4411 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.93 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.68 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.901 Division of Infectious Diseases

location_facility: 1182.17.26 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.129 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.87 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.53 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.3101 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4418 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.3210 Centre Hospitalier de Luxembourg

location_facility: 1182.17.89 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.142 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.0409 Ospedale Santa Maria Annunziata

location_facility: 1182.17.903 Montreal Chest Institute, McGill University Health Centre

location_facility: 1182.17.58 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.0393 Fondazione Centro S. Raffaele del Monte Tabor

location_facility: 1182.17.102 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.718 Complejo Hospitalario Xeral - Cíes

location_facility: 1182.17.4408 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.0419 I Cattedra Malattie Infettive

location_facility: 1182.17.713 Hospital Universitario Vírgen del Rocío

location_facility: 1182.17.910 Sunnybrook & Women's College Health Science Centre

location_facility: 1182.17.46 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.130 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.907 University Health Network - Toronto General Hospital

location_facility: 1182.17.402 Taylor Square Private Clinic

location_facility: 1182.17.3009 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.717 Hospital Clínico Universitario Vírgen de la Victoria

location_facility: 1182.17.4104 Département de médicine interne Div. Des maladies infectieus

location_facility: 1182.17.4406 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.136 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.5 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.00334 Hôpital de la Pitié Salpêtrière

location_facility: 1182.17.0395 Azienda Policlinico Umberto I

location_facility: 1182.17.3007 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.8 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.21 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.701 Hospital Clínico y Provincial de Barcelona

location_facility: 1182.17.4906 ID-Ambulanz Klinikum Dortmund

location_facility: 1182.17.3004 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.74 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.60 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.905 Canadian Immunodeficiency Research Collaborative Inc.

location_facility: 1182.17.79 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.131 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.69 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.904 Clinique Medicale Du Quartier Latin

location_facility: 1182.17.4505 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.30 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.705 Hospital Germans Trias i Pujol

location_facility: 1182.17.67 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.5505 Instituto A-Z de Pesquisa e Ensino da PUC

location_facility: 1182.17.99 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4414 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.5507 Hospital Geral de Nova Iguaçu - Ministério da Saúde

location_facility: 1182.17.3105 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.23 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.100 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.0413 Ospedale di Circolo di Busto

location_facility: 1182.17.00335 Hôpital Bichat Claude Bernard

location_facility: 1182.17.4409 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.70 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4902 Charite, Campus Virchow-Klinikum

location_facility: 1182.17.135 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.118 Early Intervention Program (EIP) Clinic

location_facility: 1182.17.122 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4101 DIM / Abteilung für Infektiologie

location_facility: 1182.17.902 Downtown Infectious Diseases Clinic

location_facility: 1182.17.18 Vanderbilt AIDS Clinical Trials Center

location_facility: 1182.17.75 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.9 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.51 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.913 McMaster University Medical Centre

location_facility: 1182.17.106 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4923 Facharzt für Innere Medizin,

location_facility: 1182.17.4301 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4928 Facharzt für Innere Medizin/Rheumatologie

location_facility: 1182.17.65 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.3201 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.5502 Farmácia do Instituto de Pesquisa Evandro Chagas

location_facility: 1182.17.47 University of Southern California

location_facility: 1182.17.96 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.128 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.115 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.126 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.73 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.86 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4102 Departement für Innere Medizin

location_facility: 1182.17.54 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.52 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.63 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.714 Hospital General Universitario de Valencia

location_facility: 1182.17.4501 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.3003 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.94 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4405 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.36 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.125 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.31 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.4404 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.110 Boehringer Ingelheim Investigational Site

location_facility: 1182.17.7 Boehringer Ingelheim Investigational Site

intervention_type: Drug

lead_sponsor_type: industriel

status_simplified: Completed


title: Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients (RESIST 2: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients With Tipranavir)

summary: The objective of this study is to demonstrate the safety and efficacy of tipranavir/ritonavir versus an active control arm in highly treatment experienced Human immunodeficiency virus-1 infected patients. Patients must have a viral load > =1000 cells/mL, and genotype indicating at least one resistance conferring protease inhibitor-mutation as determined from a predefined panel of mutations. Any CD4+ count is acceptable.

ReferenceCitation: Mikl J, Sulkowski MS, Benhamou Y, Dieterich D, Pol S, Rockstroh J, Robinson PA, Ranga M, Stern JO. Hepatic profile analyses of tipranavir in Phase II and III clinical trials. BMC Infect Dis. 2009 Dec 14;9:203. doi: 10.1186/1471-2334-9-203.

family: Mikl

full_name: Jaromir Mikl

given: Jaromir

family: Sulkowski

full_name: Mark S Sulkowski

given: Mark S

family: Benhamou

full_name: Yves Benhamou

given: Yves

family: Dieterich

full_name: Douglas Dieterich

given: Douglas

family: Pol

full_name: Stanislas Pol

given: Stanislas

family: Rockstroh

full_name: Jürgen Rockstroh

given: Jürgen

family: Robinson

full_name: Patrick A Robinson

given: Patrick A

family: Ranga

full_name: Mithun Ranga

given: Mithun

family: Stern

full_name: Jerry O Stern

given: Jerry O

currency_apc_doaj: GBP

journal_name: BMC Infectious Diseases

oa_colors: green gold

evidence: oa journal (via doaj)

license: cc-by

license_normalized: cc-by

evidence: oa repository (via OAI-PMH doi match)

repository_institution: PubMed Central - Europe PMC

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer

publisher_group: Springer

publisher_normalized: Springer

ReferenceCitation: Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H; RESIST investigator group. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006 Aug 5;368(9534):466-75.

location_country:
Italy
Austria
Brazil
Sweden
Switzerland
Mexico
Netherlands
Spain
France
Greece
Ireland
Argentina
Belgium
Portugal
Denmark
Germany
United Kingdom

location_facility: 1182.48.3317 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.5505 Instituto A-Z de Pesquisa e Ensino da PUC

location_facility: 1182.48.4918 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4408 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3303 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4911 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3323 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4924 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4603 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3305 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3308 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4414 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3935 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3933 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.5513 UNIFESP - Centro de Pesquisa Clinica

location_facility: 1182.48.5504 Hospital do Servidor Público Estadual - IAMSPE

location_facility: 1182.48.3531 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4908 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3005 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3502 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3927 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3108 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3915 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3309 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3912 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4505 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3414 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4417 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3104 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4502 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3919 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3924 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3921 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4405 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3307 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.5510 INCOR e Hospital das Clínicas da Universidade de São Paulo

location_facility: 1182.48.3110 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3905 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3320 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3501 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3920 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3010 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3417 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3926 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4407 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.5501 Clínica de Doenças Parasitárias e Infecciosas-Hospital Dia

location_facility: 1182.48.4914 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3301 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3917 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4916 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4909 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3008 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4404 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3902 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3311 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3922 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4929 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3931 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3306 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4601 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3929 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3003 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3934 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.5511 Universidade Federal da Bahia-Unidade Docente Assistencial d

location_facility: 1182.48.3932 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4913 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3312 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4910 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3930 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3407 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3210 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.5506 Centro de Referência e Treinamento - DST/AIDS

location_facility: 1182.48.4915 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4412 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4902 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.5512 Cidade Universitária Zeferino Vaz-Clínica Médica FCM

location_facility: 1182.48.4104 Hopital Universitaire de Genève

location_facility: 1182.48.5507 Hospital Geral de Nova Iguaçu - Ministério da Saúde

location_facility: 1182.48.4501 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3404 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4927 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3418 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.5503 I.I. Emilio Ribas - Moléstias Infecciosas

location_facility: 1182.48.3310 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3408 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4931 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3405 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.5509 Universidade Federal do Rio de Janeiro

location_facility: 1182.48.3315 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3906 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3207 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3313 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3009 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4921 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3403 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4901 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3904 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3925 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3302 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3206 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3106 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4301 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4409 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3909 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4920 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4504 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3304 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3503 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3402 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4926 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4912 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3411 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3002 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3318 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3908 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3101 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3412 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3916 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3007 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4907 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3202 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4906 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3409 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4919 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3316 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3321 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4406 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3209 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4411 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4928 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4904 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.5406 Servicio de Immunocomprometido

location_facility: 1182.48.3406 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3413 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4905 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3004 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3314 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3006 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3420 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3903 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3001 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3914 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3910 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3901 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3401 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3410 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4418 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3907 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4930 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3105 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4923 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3201 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4602 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3322 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.4903 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3416 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3415 Boehringer Ingelheim Investigational Site

location_facility: 1182.48.3319 Boehringer Ingelheim Investigational Site


ReferenceCitation: Ratjen F, Koker P, Geller DE, Langellier-Cocteaux B, Le Maulf F, Kattenbeck S, Moroni-Zentgraf P, Elborn JS; Tiotropium Cystic Fibrosis Study Group. Tiotropium Respimat in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials. J Cyst Fibros. 2015 Sep;14(5):608-14. doi: 10.1016/j.jcf.2015.03.004. Epub 2015 Mar 26.

family: Ratjen

full_name: Felix Ratjen

given: Felix

family: Koker

full_name: Paul Koker

given: Paul

family: Geller

full_name: David E. Geller

given: David E.

family: Langellier-Cocteaux

full_name: Berengere Langellier-Cocteaux

given: Berengere

family: Le Maulf

full_name: Florence Le Maulf

given: Florence

family: Kattenbeck

full_name: Sabine Kattenbeck

given: Sabine

family: Moroni-Zentgraf

full_name: Petra Moroni-Zentgraf

given: Petra

family: Elborn

full_name: J. Stuart Elborn

given: J. Stuart

journal_name: Journal of Cystic Fibrosis

evidence: open (via crossref license)

license: elsevier-specific: oa user license

license_normalized: elsevier-specific

repository_institution: Queen's University Belfast - Research Portal

repositories_institution: Queen's University Belfast - Research Portal

title: Tiotropium Respimat® in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials

design_allocation: Randomized

location_country:
Italy
Austria
United States
South Africa
Switzerland
Spain
United Kingdom
Germany
France
Poland
Israel
Slovakia
Hungary
Australia
Belgium
Ireland
Portugal
Russian Federation
Canada
Czech Republic

location_facility: 205.438.97001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.61003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33005 Boehringer Ingelheim Investigational Site

location_facility: 205.438.48002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.32002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.39002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.42103 Boehringer Ingelheim Investigational Site

location_facility: 205.438.97003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.35301 Boehringer Ingelheim Investigational Site

location_facility: 205.438.02007 Boehringer Ingelheim Investigational Site

location_facility: 205.438.42002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.97004 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01012 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33010 Boehringer Ingelheim Investigational Site

location_facility: 205.438.07005 Boehringer Ingelheim Investigational Site

location_facility: 205.438.61004 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33007 Boehringer Ingelheim Investigational Site

location_facility: 205.438.34002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.44003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.48003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.48001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.49008 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33008 Boehringer Ingelheim Investigational Site

location_facility: 205.438.34004 Boehringer Ingelheim Investigational Site

location_facility: 205.438.44004 Boehringer Ingelheim Investigational Site

location_facility: 205.438.49006 Boehringer Ingelheim Investigational Site

location_facility: 205.438.49002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.49003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.02003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.02004 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33006 Boehringer Ingelheim Investigational Site

location_facility: 205.438.43002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.07003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.27001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.41002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.35002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.02001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33011 Boehringer Ingelheim Investigational Site

location_facility: 205.438.36002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.44002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.42004 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01011 Boehringer Ingelheim Investigational Site

location_facility: 205.438.42101 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01006 Boehringer Ingelheim Investigational Site

location_facility: 205.438.49012 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01005 Boehringer Ingelheim Investigational Site

location_facility: 205.438.61002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33009 Boehringer Ingelheim Investigational Site

location_facility: 205.438.44005 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33013 Boehringer Ingelheim Investigational Site

location_facility: 205.438.44007 Boehringer Ingelheim Investigational Site

location_facility: 205.438.35001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.07004 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01004 Boehringer Ingelheim Investigational Site

location_facility: 205.438.42003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.49001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.36004 Boehringer Ingelheim Investigational Site

location_facility: 205.438.35003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.07001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.34005 Boehringer Ingelheim Investigational Site

location_facility: 205.438.49007 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.02006 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01008 Boehringer Ingelheim Investigational Site

location_facility: 205.438.36003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.32003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.32001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.49005 Boehringer Ingelheim Investigational Site

location_facility: 205.438.32004 Boehringer Ingelheim Investigational Site

location_facility: 205.438.39003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.44009 Boehringer Ingelheim Investigational Site

location_facility: 205.438.07002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.41004 Boehringer Ingelheim Investigational Site

location_facility: 205.438.34001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.41001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.43001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01014 Boehringer Ingelheim Investigational Site

location_facility: 205.438.41003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.61001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.49011 Boehringer Ingelheim Investigational Site

location_facility: 205.438.97002 Boehringer Ingelheim Investigational Site

location_facility: 205.438.42001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01021 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01018 Boehringer Ingelheim Investigational Site

location_facility: 205.438.02005 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33015 Boehringer Ingelheim Investigational Site

location_facility: 205.438.35004 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01007 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33004 Boehringer Ingelheim Investigational Site

location_facility: 205.438.39001 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01013 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01010 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01003 Boehringer Ingelheim Investigational Site

location_facility: 205.438.33014 Boehringer Ingelheim Investigational Site

location_facility: 205.438.01019 Boehringer Ingelheim Investigational Site

location_facility: 205.438.42102 Boehringer Ingelheim Investigational Site

type: EudraCT Number

source: euctr

title: A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.

summary: To date, there have been no formal clinical studies completed using tiotropium in CF patients. While there is a large body of evidence demonstrating the efficacy and safety of tiotropium in patients with Chronic Obstructive Pulmonary Disease (COPD), relatively little is known about its efficacy and safety in patients with a diagnosis of cystic fibrosis. Therefore, Boehringer Ingelheim proposed to profile the long acting anticholinergic tiotropium and to generate adequate clinical data for use as a bronchodilator in paediatric and adult CF. The phase III trial (205.438) is a part of the approved Paediatric Investigation Plan (PIP) agreed for Spiriva® Respimat® in Cystic Fibrosis.


ReferenceType: background

ReferenceCitation: Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800.

ReferenceCitation: Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, McElhaney JE, Vesikari T, Andrews C, Choi WS, Esen M, Ikematsu H, Choma MK, Pauksens K, Ravault S, Salaun B, Schwarz TF, Smetana J, Abeele CV, Van den Steen P, Vastiau I, Weckx LY, Levin MJ; ZOE-50/70 Study Group. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. J Infect Dis. 2018 May 5;217(11):1750-1760. doi: 10.1093/infdis/jiy095.

ReferenceCitation: Ikematsu H et al. (2018) Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi. 92(2):103-114.

ReferenceCitation: Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, Volpi A, Heineman TC; ZOE-50/70 Study Group. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018 Mar 14;36(12):1537-1541. doi: 10.1016/j.vaccine.2018.02.029. Epub 2018 Feb 17.

ReferenceCitation: Kim JH, Diaz-Decaro J, Jiang N, Hwang SJ, Choo EJ, Co M, Hastie A, Hui DSC, Irimajiri J, Lee J, Leung EM, Tang H, Tsuru T, Watson P, Wu Z, Yu CJ, Yuan Y, Zahaf T, Cunningham AL, Schuind A. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. Hum Vaccin Immunother. 2021 Jul 3;17(7):2050-2057. doi: 10.1080/21645515.2020.1859321. Epub 2021 Feb 19.

family: Kim

full_name: Joon Hyung Kim

given: Joon Hyung

family: Diaz-Decaro

full_name: John Diaz-Decaro

given: John

family: Jiang

full_name: Ning Jiang

given: Ning

name: Department of Family Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan

name: National Yang Ming University School of Medicine, Taipei City, Taiwan

family: Hwang

full_name: Shinn-Jang Hwang

given: Shinn-Jang

name: Department of Infectious Diseases, SoonChunhyang University Bucheon Hospital, Bucheon-si, Republic of Korea

family: Choo

full_name: Eun Ju Choo

given: Eun Ju

family: Co

full_name: Maribel Co

given: Maribel

family: Hastie

full_name: Andrew Hastie

given: Andrew

name: Department of Medicine and Therapeutics, The Chinese University of Hong Kong Prince of Wales Hospital, Sha Tin, Hong Kong

family: Hui

full_name: David Shu Cheong Hui

given: David Shu Cheong

name: Department of Dermatology, Shonan Kamakura General Hospital, Kanagawa, Japan

family: Irimajiri

full_name: Junya Irimajiri

given: Junya

name: Department of Internal Medicine, Division of Infectious Diseases, Kangnam Sacred Heart Hospital, Seoul, Republic of Korea

family: Lee

full_name: Jacob Lee

given: Jacob

name: Department of Medicine and Geriatrics, Division of Geriatric Medicine and Rehabilitation, United Christian Hospital, Kwun Tong, Hong Kong

family: Leung

full_name: Edward Man-Fuk Leung

given: Edward Man-Fuk

family: Tang

full_name: Haiwen Tang

given: Haiwen

name: Medical CO.LTA PS Clinic, Fukuoka, Japan

family: Tsuru

full_name: Tomomi Tsuru

given: Tomomi

family: Watson

full_name: Philip Watson

given: Philip

family: Wu

full_name: Zhenhua Wu

given: Zhenhua

name: Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan

name: National Taiwan University Hospital Biomedical Park Branch Hospital, Zhubei City, Hsinchu County, Taiwan

family: Yu

full_name: Chong-Jen Yu

given: Chong-Jen

family: Yuan

full_name: Yanfei Yuan

given: Yanfei

family: Zahaf

full_name: Toufik Zahaf

given: Toufik

name: The Westmead Institute for Medical Research, Westmead, Australia

family: Cunningham

full_name: Anthony L. Cunningham

given: Anthony L.

family: Schuind

full_name: Anne Schuind

given: Anne

journal_name: Human Vaccines & Immunotherapeutics

ReferenceCitation: Dagnew AF, Rausch D, Hervé C, Zahaf T, Levin MJ, Schuind A; ZOE-50/70 study group. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford). 2021 Mar 2;60(3):1226-1233. doi: 10.1093/rheumatology/keaa424.

name: Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

ReferenceCitation: Colindres R, Wascotte V, Brecx A, Clarke C, Hervé C, Kim JH, Levin MJ, Oostvogels L, Zahaf T, Schuind A, Cunningham AL. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother. 2020 Nov 1;16(11):2628-2633. doi: 10.1080/21645515.2020.1741312. Epub 2020 Apr 29.

name: independent Biotech and Vaccines Consultant

name: The Westmead Institute for Medical Research, University of Sydney, Sydney, Australia

ReferenceCitation: Willer DO, Oostvogels L, Cunningham AL, Gervais P, Gorfinkel I, Hyung Kim J, Talarico C, Wascotte V, Zahaf T, Colindres R, Schuind A; ZOE 50/70 study groups. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. Vaccine. 2019 Oct 8;37(43):6262-6267. doi: 10.1016/j.vaccine.2019.09.028. Epub 2019 Sep 16.

ReferenceCitation: López-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, Diez-Domingo J, Heineman TC, Lal H, McElhaney JE, McNeil SA, Yeo W, Tavares-Da-Silva F; ZOE-50/70 Study Group. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. Vaccine. 2019 Apr 24;37(18):2482-2493. doi: 10.1016/j.vaccine.2019.03.043. Epub 2019 Mar 29.

evidence: oa repository (via OAI-PMH title and first author match)

repository_institution: University of Wollongong - Research Online

repository_institution: Tampere University - Tampere University Institutional Repository

repository_institution: KTH Royal Institute of Technology - KTH Publication Database DiVA

repository_institution: Uppsala University - Uppsala University Publications

ReferenceCitation: Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, Berglund J, Campora L, de Looze F, Korhonen T, Leung E, Levin M, Volpi A, Johnson RW; ZOE-50/70 Study Group. Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older. J Gerontol A Biol Sci Med Sci. 2019 Jul 12;74(8):1231-1238. doi: 10.1093/gerona/gly150.

name: Freelance, on behalf of GSK, Wavre, Belgium

name: Health Sciences North Research Institute, Sudbury, Ontario, Canada

name: Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Canada

name: Diagnostics Research Group, San Antonio, Texas

name: Department of Infectious Disease, Barwon Health, Deakin University, Geelong, Victoria, Australia

name: Department of Medical Radiation Physics, Karolinska University Hospital, Stockholm, Sweden

name: Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden

name: AusTrials Pty Ltd, Sherwood, Queensland, Australia

name: School of Medicine, University of Queensland, Brisbane, Australia

name: Tampere Vaccine Research Clinic, Tampere, Finland

name: United Christian Hospital, Kowloon, Hong Kong

name: Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora

ipd_sharing_description: IPD for this study will be made available via the Clinical Study Data Request site.

location_country:
Italy
Brazil
United States
Sweden
Hong Kong
Mexico
Germany
Finland
France
Czechia
Japan
Australia
Spain
Estonia
Canada
United Kingdom
Korea, Republic of
Taiwan

title: Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older

summary:
The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 70 years.

Two studies (Zoster-006 [NCT01165177] and Zoster-022 [NCT01165229]) will be conducted concurrently to evaluate efficacy of GSK1437173A vaccine. A pooled analysis of data from both studies combined will be conducted contingent on each study achieving its objectives. This protocol posting also deals with the outcome measures related to the pooled analysis.


title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer

acronym: REDUCE

summary: This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.

study_completion_date_type: Actual

primary_purpose: Prevention

ReferenceCitation: Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB Jr, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol. 2012 Dec;62(6):953-61. doi: 10.1016/j.eururo.2012.05.006. Epub 2012 May 12.

ReferenceCitation: Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL, Groskopf J. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol. 2010 Nov;184(5):1947-52. doi: 10.1016/j.juro.2010.06.098. Epub 2010 Sep 17.

ReferenceCitation: Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ. Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis. 2011 Dec;14(4):326-31. doi: 10.1038/pcan.2011.28. Epub 2011 Jun 28.

ReferenceCitation: Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Urology. 2011 Sep;78(3):641-6. doi: 10.1016/j.urology.2011.03.063. Epub 2011 Jul 20.

ReferenceCitation: Bostwick DG, Qian J, Drewnowska K, Varvel S, Bostwick KC, Marberger M, Rittmaster RS. Prostate needle biopsy quality in reduction by dutasteride of prostate cancer events study: worldwide comparison of improvement with investigator training and centralized laboratory processing. Urology. 2010 Jun;75(6):1406-10. doi: 10.1016/j.urology.2009.07.1348. Epub 2009 Nov 25.

ReferenceCitation: Crawford ED, Andriole GL, Marberger M, Rittmaster RS. Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology. 2010 Mar;75(3):502-9. doi: 10.1016/j.urology.2009.05.099. Epub 2009 Dec 29. Review.

ReferenceCitation: Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

ReferenceCitation: Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, Tammela TL, Teloken C, Tindall D, Freedland SJ, Somerville MC, Wilson TH, Fowler I, Castro R, Rittmaster RS; REDUCE Study Group. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol. 2011 Jan;185(1):126-31. doi: 10.1016/j.juro.2010.09.011. Epub 2010 Nov 12.

ReferenceCitation: Nickel JC, Roehrborn C, Montorsi F, Wilson TH, Rittmaster RS. Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. J Urol. 2011 Oct;186(4):1313-8. doi: 10.1016/j.juro.2011.05.071. Epub 2011 Aug 17.

ReferenceCitation: Thomas JA 2nd, Gerber L, Moreira DM, Hamilton RJ, Bañez LL, Castro-Santamaria R, Andriole GL, Isaacs WB, Xu J, Freedland SJ. Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). J Intern Med. 2012 Jul;272(1):85-92. doi: 10.1111/j.1365-2796.2011.02504.x. Epub 2012 Jan 16.

ReferenceCitation: Marberger M, McConnell JD, Fowler I, Andriole GL, Bostwick DG, Somerville MC, Rittmaster RS. Biopsy misidentification identified by DNA profiling in a large multicenter trial. J Clin Oncol. 2011 May 1;29(13):1744-9. doi: 10.1200/JCO.2010.32.1646. Epub 2011 Mar 28.

ReferenceCitation: Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int. 2012 Apr;109(8):1162-9. doi: 10.1111/j.1464-410X.2011.10373.x. Epub 2011 Jun 23.

ReferenceCitation: Marberger M, Wilson TH, Rittmaster RS. Low serum testosterone levels are poor predictors of sexual dysfunction. BJU Int. 2011 Jul;108(2):256-62. doi: 10.1111/j.1464-410X.2010.09766.x. Epub 2010 Oct 18.

ReferenceCitation: Kattan MW, Earnshaw SR, McDade CL, Black LK, Andriole GL. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Appl Health Econ Health Policy. 2011 Sep 1;9(5):305-15. doi: 10.2165/11592200-000000000-00000.

ReferenceCitation: Muller RL, Gerber L, Moreira DM, Andriole G, Castro R, Freedland SJ. Baseline Serum Testosterone and DHT Levels and the Risk of Prostate Cancer Detection in the Placebo Arm of the REDUCE Trial. [Eur Urol [E-pub 18 May]]. 2012;

ReferenceCitation: Newcombe PJ, Reck BH, Sun J, Platek GT, Verzilli C, Kader AK, Kim ST, Hsu FC, Zhang Z, Zheng SL, Mooser VE, Condreay LD, Spraggs CF, Whittaker JC, Rittmaster RS, Xu J. A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk. Genet Epidemiol. 2012 Jan;36(1):71-83. doi: 10.1002/gepi.21600.

ReferenceCitation: Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster RS, Andriole GL, Groskopf J. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial. Urology. 2011 Aug;78(2):380-5. doi: 10.1016/j.urology.2011.03.033.

ReferenceCitation: Stephen J. Freedland, Leah Gerber, Lionel Banez, Daniel Moreira, Gerald L. Andriole, and Roger S. Rittmaster on behalf of the REDUCE Study Group. Statin Use and the Risk of Prostate Cancer and High-grade Prostate Cancer: Results from the REDUCE study. [AUA 2011 Annual Meeting]. 2011;185(4 Suppl):e135.

ReferenceCitation: Thomas JA 2nd, Gerber L, Bañez LL, Moreira DM, Rittmaster RS, Andriole GL, Freedland SJ. Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):576-81. doi: 10.1158/1055-9965.EPI-11-1017. Epub 2012 Feb 7.

ReferenceCitation: Vidal AC, Oyekunle T, Feng T, Freedland AR, Moreira D, Castro-Santamaria R, Andriole GL, Freedland SJ, Allott EH. Asian Race and Risk of Prostate Cancer: Results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev. 2020 Nov;29(11):2165-2170. doi: 10.1158/1055-9965.EPI-20-0646. Epub 2020 Aug 20.

family: Vidal

full_name: Adriana C. Vidal

given: Adriana C.

family: Oyekunle

full_name: Taofik Oyekunle

given: Taofik

family: Feng

full_name: Tom Feng

given: Tom

family: Freedland

full_name: Alexis R. Freedland

given: Alexis R.

family: Moreira

full_name: Daniel Moreira

given: Daniel

family: Castro-Santamaria

full_name: Ramiro Castro-Santamaria

given: Ramiro

family: Andriole

full_name: Gerald L. Andriole

given: Gerald L.

full_name: Stephen J. Freedland

given: Stephen J.

family: Allott

full_name: Emma H. Allott

given: Emma H.

journal_name: Cancer Epidemiology Biomarkers & Prevention

oa_colors: green other

evidence: open (via free pdf)

publisher: American Association for Cancer Research (AACR)

ReferenceCitation: Bliwise DL, Howard LE, Moreira DM, Andriole GL, Hopp ML, Freedland SJ. Nocturia and associated mortality: observational data from the REDUCE trial. Prostate Cancer Prostatic Dis. 2019 Mar;22(1):77-83. doi: 10.1038/s41391-018-0090-5. Epub 2018 Sep 13.

family: Bliwise

full_name: Donald L. Bliwise

given: Donald L.

family: Howard

full_name: Lauren E. Howard

given: Lauren E.

full_name: Daniel M. Moreira

given: Daniel M.

family: Hopp

full_name: Martin L. Hopp

given: Martin L.

ReferenceCitation: Moreira DM, Andriole GL, Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ. Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations. World J Urol. 2017 Oct;35(10):1525-1530. doi: 10.1007/s00345-017-2036-2. Epub 2017 Apr 10.

ReferenceCitation: Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, Moreira DM. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention. J Urol. 2016 Nov;196(5):1493-1498. doi: 10.1016/j.juro.2016.06.090. Epub 2016 Jul 1.

name: Department of Urology, Queen's University, Kingston, Ontario, Canada

name: Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas

name: Department of Urology, Mayo Clinic, Rochester, Minnesota

name: Global R&D Unit, GlaxoSmithKline, Inc., King of Prussia, Pennsylvania

name: Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California

publisher: Ovid Technologies (Wolters Kluwer Health)

ReferenceCitation: Moreira DM, Nickel JC, Andriole GL, Castro-Santamaria R, Freedland SJ. Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study. Prostate. 2015 Sep;75(13):1492-8. doi: 10.1002/pros.23041. Epub 2015 Jul 17.

name: Department of Urology; Mayo Clinic; Rochester Minnesota

name: Department of Urology; Queen's University; Kingston ON Canada

name: Department of Surgery, Division of Urologic Surgery; Washington University School of Medicine; St. Louis Missouri

name: GlaxoSmithKline Inc.; Global R&D Unit; King of Prussia Pennsylvania

name: Department of Surgery, Division of Urology; Cedars-Sinai Medical Center; Los Angeles California

ReferenceCitation: Moreira DM, Bostwick DG, Andriole GL, Peterson BL, Cohen HJ, Castro-Santamaria R, Freedland SJ. Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy. J Urol. 2015 Nov;194(5):1241-6. doi: 10.1016/j.juro.2015.05.103. Epub 2015 Jul 10.

name: Bostwick Laboratories, Inc., Glen Allen, Virginia

name: Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri

name: Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina

name: Department of Medicine, Duke University School of Medicine, Durham, North Carolina

name: GlaxoSmithKline, Inc., Global R & D Unit, King of Prussia, Pennsylvania

name: Urology Section, Veterans Affairs Medical Center, Durham, North Carolina

name: Division of Urology, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, California

ReferenceCitation: Toren P, Margel D, Kulkarni G, Finelli A, Zlotta A, Fleshner N. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. BMJ. 2013 Apr 15;346:f2109. doi: 10.1136/bmj.f2109.

ReferenceCitation: Muller RL, Gerber L, Moreira DM, Andriole G Jr, Hamilton RJ, Fleshner N, Parsons JK, Freedland SJ. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. Eur Urol. 2013 Jun;63(6):1115-21. doi: 10.1016/j.eururo.2013.02.038. Epub 2013 Mar 7.

title: Obesity Is Associated with Increased Prostate Growth and Attenuated Prostate Volume Reduction by Dutasteride

ReferenceCitation: Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol. 2012 Nov;62(5):757-64. doi: 10.1016/j.eururo.2012.05.025. Epub 2012 May 18.

title: Serum Testosterone and Dihydrotestosterone and Prostate Cancer Risk in the Placebo Arm of the Reduction by Dutasteride of Prostate Cancer Events Trial

ipd_sharing_description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

location_country:
Finland
Greece
Romania
Australia
Belgium
Russian Federation
Denmark
Ukraine
Spain
Croatia
France
Japan
Lithuania
Poland
Norway
Slovakia
Argentina
Canada
Slovenia
Turkey
South Africa
Chile
Sweden
Switzerland
Netherlands
Bulgaria
Hungary
Ireland
Puerto Rico
Portugal
Germany
United States
United Kingdom
Italy
Austria
Brazil
Mexico
Tunisia
New Zealand
Belarus
Estonia
Latvia


type: Other Identifier

title: BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma

summary:
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating stage III or stage IV Hodgkin's lymphoma.

PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have stage III or stage IV Hodgkin's lymphoma.

study_start_date_type: Actual

status: Active, not recruiting

ReferenceCitation: Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016 Jun 10;34(17):2028-36. doi: 10.1200/JCO.2015.64.5648. Epub 2016 Apr 25.

name: Patrice Carde and Christophe Ferme, Gustave Roussy Cancer Campus, Villejuif; Pauline Brice, Hopital St. Louis, Paris; Olivier Casasnovas and Denis Caillot, Centre Hospitalier Universitaire (CHU) de Dijon, Dijon; Isabelle Gaillard, CHU Henri Mondor, Creteil; Serge Bologna, Centre Hospitalier Regional Universitaire (CHR) de Nancy, Nancy; Frank Morschhauser, CHR de Lille, Lille; Bertrand Coiffier, CHU de Lyon, Lyon; Nicolas Mounier, Hopital de L’Archet, Nice, France; Matthias Karrasch and Catherine Fortpied...

family: Carde

full_name: Patrice Carde

given: Patrice

family: Karrasch

full_name: Matthias Karrasch

given: Matthias

family: Fortpied

full_name: Catherine Fortpied

given: Catherine

family: Brice

full_name: Pauline Brice

given: Pauline

family: Khaled

full_name: Hussein Khaled

given: Hussein

family: Casasnovas

full_name: Olivier Casasnovas

given: Olivier

family: Caillot

full_name: Denis Caillot

given: Denis

family: Gaillard

full_name: Isabelle Gaillard

given: Isabelle

family: Bologna

full_name: Serge Bologna

given: Serge

family: Ferme

full_name: Christophe Ferme

given: Christophe

family: Lugtenburg

full_name: Pieternella Johanna Lugtenburg

given: Pieternella Johanna

family: Morschhauser

full_name: Frank Morschhauser

given: Frank

family: Aurer

full_name: Igor Aurer

given: Igor

family: Coiffier

full_name: Bertrand Coiffier

given: Bertrand

family: Meyer

full_name: Ralph Meyer

given: Ralph

family: Seftel

full_name: Matthew Seftel

given: Matthew

family: Wolf

full_name: Max Wolf

given: Max

family: Glimelius

full_name: Bengt Glimelius

given: Bengt

family: Sureda

full_name: Anna Sureda

given: Anna

family: Mounier

full_name: Nicolas Mounier

given: Nicolas

journal_name: Journal of Clinical Oncology

publisher: American Society of Clinical Oncology (ASCO)

lead_sponsor: European Organisation for Research and Treatment of Cancer - EORTC

location_country:
Sweden
Netherlands
Croatia
Czechia
France
Poland
Hungary
Belgium
Australia
New Zealand
Spain
Canada
United Kingdom

location_facility: Centre Hospitalier Universitaire Brugmann

location_facility: Ottawa Hospital Regional Cancer Centre - General Campus

location_facility: Daniel Den Hoed Cancer Center at Erasmus Medical Center

location_facility: Centre Hospitalier Regional et Universitaire de Lille

location_facility: McGill Cancer Centre at McGill University

location_facility: Karolinska University Hospital - Huddinge

location_facility: Cancer Research Centre at Weston Park Hospital

location_facility: Edmond Odette Cancer Centre at Sunnybrook

location_facility: Centre Hospitalier Regional de la Citadelle

location_facility: Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes

location_facility: Centre Hospitalier Sud Francilien - Site Corbeil

location_facility: Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital

location_facility: Windsor Regional Cancer Centre at Windsor Regional Hospital

location_facility: Northeastern Ontario Regional Cancer Centre

location_facility: Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust

location_facility: Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle

location_facility: Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology - Warsaw

location_facility: Westmead Institute for Cancer Research at Westmead Hospital

location_facility: Nepean Cancer Care Centre at Nepean Hospital

location_facility: Cross Cancer Institute at University of Alberta

location_facility: London Regional Cancer Program at London Health Sciences Centre

location_facility: Centre Hospitalier Universitaire de Quebec

location_facility: Cancer Centre of Southeastern Ontario at Kingston General Hospital

location_facility: Centre Hospitalier Universitaire Henri Mondor

location_facility: Mount Vernon Cancer Centre at Mount Vernon Hospital

location_facility: Academisch Medisch Centrum at University of Amsterdam

location_facility: Saskatoon Cancer Centre at the University of Saskatchewan

location_facility: Centre Hospitalier Notre Dame - Reine Fabiola

location_facility: Hospital Universitari Germans Trias i Pujol

location_facility: Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz

location_facility: Universitair Medisch Centrum St. Radboud - Nijmegen

location_facility: Centre Hospital Regional Universitaire de Limoges


summary: Severe sepsis is defined as a systemic inflammatory response syndrome that results from infection and is associated with acute organ dysfunction. It usually results from bacterial infections, but it may occur in response to other pathogens, such as fungi, viruses, and parasites.

lead_sponsor: Eli Lilly and Company

location_country:
Finland
Romania
Australia
Belgium
Russian Federation
Denmark
Czech Republic
Taiwan
India
Spain
France
Thailand
Slovakia
Norway
Canada
South Africa
Chile
Sweden
Saudi Arabia
Switzerland
Netherlands
Singapore
Germany
United States
United Kingdom
Italy
Austria
Brazil
Lebanon
Mexico
Egypt
New Zealand

location_facility: timoreFor additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.

location_facility: For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.


title: Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen

acronym: IES

summary: To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.

lead_sponsor: Pfizer

location_country:
Luxembourg
Peru
Greece
Romania
Belgium
Australia
Russian Federation
Denmark
Czech Republic
Spain
Croatia
France
Poland
Slovakia
Norway
Argentina
Slovenia
South Africa
Sweden
Hong Kong
Netherlands
Switzerland
Bulgaria
Malta
Hungary
Ireland
Portugal
Germany
United States
United Kingdom
Italy
Bosnia and Herzegovina
Serbia
Israel
Egypt
New Zealand
Estonia


title: Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy

summary:
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for urinary tract cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin plus gemcitabine with or without paclitaxel in treating patients who have stage IV urinary tract cancer.

ReferenceType: result

ReferenceCitation: Bellmunt J, von der Maase H, Mead GM, et al.: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy: EORTC30987/Intergroup study. [Abstract] J Clin Oncol 25 (Suppl 18): A-LBA5030, 242s, 2007.

location_country:
Italy
Austria
United States
Netherlands
Germany
France
Poland
Israel
Slovakia
Hungary
Australia
Belgium
Spain
Denmark
Canada
United Kingdom

location_facility: St. Louis University Hospital Cancer Center

location_facility: Southwest Cancer and Research Center at University Medical Center

location_facility: City of Hope Comprehensive Cancer Center

location_facility: Veterans Affairs Medical Center - Seattle

location_facility: Veterans Affairs Medical Center - Amarillo

location_facility: Daniel Den Hoed Cancer Center at Erasmus Medical Center

location_facility: Klinikum der Stadt Ludwigshafen am Rhein

location_facility: Hospital Universitario Marques de Valdecilla

location_facility: University of Mississippi Medical Center

location_facility: Swedish Cancer Institute at Swedish Medical Center - First Hill Campus

location_facility: Klinikum der Friedrich-Schiller Universitaet Jena

location_facility: Josephine Ford Cancer Center at Henry Ford Hospital

location_facility: Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin

location_facility: Veterans Affairs Medical Center - Biloxi

location_facility: University of Colorado Cancer Center at University of Colorado Health Sciences Center

location_facility: University of Tennessee Cancer Institute

location_facility: Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital

location_facility: Veterans Affairs Medical Center - Little Rock (McClellan)

location_facility: Hospital Clinico Universitario de Valencia

location_facility: Veterans Affairs Medical Center - Portland

location_facility: Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)

location_facility: James P. Wilmot Cancer Center at University of Rochester Medical Center

location_facility: Northern Centre for Cancer Treatment at Newcastle General Hospital

location_facility: Krankenhaus Hohe Warte Mediziniche Klinik

location_facility: Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center

location_facility: University of Texas - MD Anderson Cancer Center

location_facility: Arizona Cancer Center at University of Arizona Health Sciences Center

location_facility: Charles M. Barrett Cancer Center at University Hospital

location_facility: Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

location_facility: Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle

location_facility: Veterans Affairs Medical Center - San Antonio (Murphy)

location_facility: University of California Davis Cancer Center

location_facility: Universitat des Saarlandes Innere Medizin 1

location_facility: University Hospital - Rotterdam Dijkzigt

location_facility: Centre de Lutte Contre le Cancer, Georges-Francois Leclerc

location_facility: Veterans Affairs Medical Center - Oklahoma City

location_facility: British Columbia Cancer Agency - Vancouver Island Cancer Centre

location_facility: Herbert Irving Comprehensive Cancer Center at Columbia University

location_facility: Veterans Affairs Medical Center - Tucson

location_facility: Cancer Care Ontario - Windsor Regional Cancer Centre

location_facility: Veterans Affairs Medical Center - Ann Arbor

location_facility: Veterans Affairs Medical Center - Jackson

location_facility: Veterans Affairs Medical Center - Shreveport

location_facility: Prostate Centre at Vancouver General Hospital

location_facility: Hospital General Universitari Vall d'Hebron

location_facility: Northeastern Ontario Regional Cancer Centre - Sudbury

location_facility: Providence Cancer Institute at Providence Hospital

location_facility: Veterans Affairs Medical Center - Cincinnati

location_facility: Academisch Ziekenhuis der Vrije Universiteit Brussel

location_facility: Nanaimo Cancer Clinic at Nanaimo Regional General Hospital

location_facility: Veterans Affairs Medical Center - Charleston

location_facility: Klinik und Poliklinik fuer Kinderheilkunde

location_facility: Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center

location_facility: University of Michigan Comprehensive Cancer Center

location_facility: Jonsson Comprehensive Cancer Center, UCLA

location_facility: USC/Norris Comprehensive Cancer Center and Hospital

location_facility: Hospital General Universitario De Guadalajara

location_facility: St. Mary's - Duluth Clinic Cancer Center

location_facility: Louisiana State University Health Sciences Center - Shreveport

location_facility: Prince Edward Island Cancer Center at Queen Elizabeth Hospital

location_facility: Cardinal Bernardin Cancer Center at Loyola University Medical Center

location_facility: Veterans Affairs Medical Center - New Orleans

location_facility: Veterans Affairs Medical Center - Memphis

location_facility: Velindre Cancer Center at Velinde Hospital

location_facility: Hamilton and District Urology Association

location_facility: Veterans Affairs Medical Center - Kansas City

location_facility: Oklahoma University Medical Center at University of Oklahoma Health Sciences Center

location_facility: Centre Hospitalier de l'Universite de Montreal

location_facility: Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology

location_facility: Veterans Affairs Medical Center - Lexington

location_facility: Guy's and St. Thomas' Hospitals NHS Trust

location_facility: University of Texas Health Science Center at San Antonio

location_facility: Sunnybrook and Women's College Health Sciences Centre

location_facility: Klinikum Rechts Der Isar - Technische Universitaet Muenchen

location_facility: Hospital Clinic y Provincial de Barcelona

location_facility: Margaret and Charles Juravinski Cancer Centre

location_facility: Durham Regional Cancer Centre at Lakeridge Health Oshawa

location_facility: Newfoundland Cancer Treatment and Research Foundation

location_facility: Hollings Cancer Center at Medical University of South Carolina

location_facility: British Columbia Cancer Agency - Centre for the Southern Interior

location_facility: Hotel Dieu Health Sciences Hospital - Niagara

location_facility: Veterans Affairs Medical Center - Salt Lake City

location_facility: Cancer Research Center at Boston Medical Center

location_facility: Cancer Care Ontario-London Regional Cancer Centre

location_facility: Northwestern Ontario Regional Cancer Care

location_facility: Markey Cancer Center at University of Kentucky Chandler Medical Center

location_facility: Centre Hospitalier Regional de Lanaudiere

location_facility: CHU Liege - Domaine Universitaire du Sart Tilman

location_facility: Toronto Sunnybrook Regional Cancer Centre

location_facility: Veterans Affairs Outpatient Clinic - Martinez

location_facility: Cancer Institute at Oregon Health and Science University

location_facility: Algoma Reginal Cancer Program at Sault Area Hospital